194 related articles for article (PubMed ID: 22099791)
1. De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients.
Novoa PA; Grinyó JM; Ramos FJ; Errasti P; Franco A; Aldana G; Pefaur J; Marti-Cuadros AM; Otero AB; Saval N; Oppenheimer F
Transplant Proc; 2011 Nov; 43(9):3331-9. PubMed ID: 22099791
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
3. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
6. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
[TBL] [Abstract][Full Text] [Related]
8. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
10. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
Nashan B; Curtis J; Ponticelli C; Mourad G; Jaffe J; Haas T;
Transplantation; 2004 Nov; 78(9):1332-40. PubMed ID: 15548972
[TBL] [Abstract][Full Text] [Related]
11. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
[TBL] [Abstract][Full Text] [Related]
13. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
[TBL] [Abstract][Full Text] [Related]
16. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
17. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
18. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
19. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.
Grushkin C; Mahan JD; Mange KC; Hexham JM; Ettenger R
Pediatr Transplant; 2013 May; 17(3):237-43. PubMed ID: 23279564
[TBL] [Abstract][Full Text] [Related]
20. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.
Pape L; Lehner F; Blume C; Ahlenstiel T
Transplantation; 2011 Sep; 92(6):658-62. PubMed ID: 21804444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]